<?xml version="1.0" encoding="UTF-8"?>
<p id="Par43">If speed to a phase 1 trial for mAb therapies has been a focus of the biopharmaceutical industry for many years, what is new about this approach for a pandemic outbreak? Benchmarking with innovator companies and CMOs suggests the current best-in-class timeline from lead identification to IND timeline is 10â€“12 months.</p>
